tiprankstipranks
Trending News
More News >

InnoCare Pharma Reports Strong Revenue Growth and Improved Profit Margins for 2024

Story Highlights
InnoCare Pharma Reports Strong Revenue Growth and Improved Profit Margins for 2024

Don’t Miss TipRanks’ Half Year Sale

The latest update is out from InnoCare Pharma Ltd. ( (HK:9969) ).

InnoCare Pharma Ltd. announced its audited consolidated financial results for the year ending December 31, 2024, reporting a significant increase in revenue and gross profit. The company’s total revenue rose by 36.7% to RMB1,009.4 million, driven by a 49.1% increase in sales of orelabrutinib, a key product, due to strong commercial execution and growth in MZL indications. Despite a loss for the year, the gross profit margin improved to 86.3%, attributed to a favorable sales mix and enhanced manufacturing efficiency. This financial performance highlights InnoCare’s strengthened market position and operational efficiency.

More about InnoCare Pharma Ltd.

InnoCare Pharma Ltd. is a pharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative drugs. The company is primarily involved in the healthcare industry, with a market focus on providing treatments for various medical conditions.

YTD Price Performance: 36.93%

Average Trading Volume: 8,505,150

Technical Sentiment Signal: Sell

Current Market Cap: HK$12.64B

For a thorough assessment of 9969 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1